IRIS - Res&Arch Institutional Research Information System - Research & Archive

FALINI, Brunangelo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.662
EU - Europa 8.335
AS - Asia 7.578
SA - Sud America 1.281
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 12
Totale 28.077
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.422
SG - Singapore 3.567
IT - Italia 1.585
IE - Irlanda 1.342
UA - Ucraina 1.169
RU - Federazione Russa 1.058
SE - Svezia 1.015
BR - Brasile 987
CN - Cina 971
HK - Hong Kong 865
VN - Vietnam 845
DE - Germania 522
FI - Finlandia 458
FR - Francia 441
KR - Corea 361
GB - Regno Unito 288
IN - India 160
TR - Turchia 132
CA - Canada 128
BD - Bangladesh 105
AR - Argentina 102
IQ - Iraq 96
NL - Olanda 82
MX - Messico 74
UZ - Uzbekistan 71
PL - Polonia 65
JP - Giappone 58
AT - Austria 54
ZA - Sudafrica 52
CH - Svizzera 49
PK - Pakistan 47
CO - Colombia 46
BE - Belgio 42
ID - Indonesia 40
EC - Ecuador 38
VE - Venezuela 37
ES - Italia 33
SA - Arabia Saudita 33
CZ - Repubblica Ceca 32
PH - Filippine 32
MA - Marocco 30
JO - Giordania 24
LB - Libano 24
ET - Etiopia 21
EG - Egitto 19
PE - Perù 18
GR - Grecia 17
CL - Cile 16
LT - Lituania 16
AZ - Azerbaigian 13
BO - Bolivia 13
KE - Kenya 13
KZ - Kazakistan 13
MY - Malesia 13
OM - Oman 13
PY - Paraguay 13
DZ - Algeria 11
NP - Nepal 11
TN - Tunisia 11
RO - Romania 10
UY - Uruguay 10
AE - Emirati Arabi Uniti 9
IL - Israele 9
PS - Palestinian Territory 9
TH - Thailandia 9
AL - Albania 8
EU - Europa 8
AU - Australia 7
CR - Costa Rica 7
JM - Giamaica 7
KG - Kirghizistan 7
PT - Portogallo 7
HU - Ungheria 6
PA - Panama 6
SN - Senegal 6
SY - Repubblica araba siriana 6
AO - Angola 5
BG - Bulgaria 5
DO - Repubblica Dominicana 5
GE - Georgia 5
NZ - Nuova Zelanda 5
RS - Serbia 5
BY - Bielorussia 4
CI - Costa d'Avorio 4
LA - Repubblica Popolare Democratica del Laos 4
QA - Qatar 4
AM - Armenia 3
IR - Iran 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
NG - Nigeria 3
NI - Nicaragua 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DK - Danimarca 2
DM - Dominica 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
Totale 28.025
Salva come PNG Salva come JPEG
Città #
Singapore 2.518
Chandler 1.507
Dublin 1.342
San Jose 1.048
Hong Kong 861
San Mateo 715
Ashburn 693
Perugia 658
Jacksonville 612
Boardman 507
Dong Ket 465
Santa Clara 400
Moscow 377
Seoul 359
Altamura 333
Medford 302
Princeton 297
Lauterbourg 289
Wilmington 248
Lawrence 232
Beijing 217
Ann Arbor 201
Andover 197
Munich 167
Los Angeles 147
New York 142
Ho Chi Minh City 134
The Dalles 127
Helsinki 124
Piscataway 119
Des Moines 99
Hanoi 85
Saint Petersburg 85
São Paulo 83
Turku 80
Shanghai 69
Dallas 67
Norwalk 67
Izmir 59
Orem 56
Tokyo 53
Council Bluffs 52
Frankfurt am Main 51
Woodbridge 49
Falls Church 47
Rome 47
London 44
Houston 43
Nuremberg 43
Amsterdam 42
Baghdad 41
Brussels 41
San Paolo di Civitate 41
Brooklyn 38
Tashkent 38
Belo Horizonte 36
Chennai 35
Montreal 35
Redmond 35
Johannesburg 34
Chicago 33
Rio de Janeiro 32
Warsaw 31
Ottawa 30
Denver 27
Manchester 27
Redwood City 27
San Francisco 27
Stockholm 27
Mexico City 24
Haiphong 22
Atlanta 21
Foligno 21
Phoenix 21
Amman 20
Toronto 20
Addis Ababa 19
Ankara 19
Boston 19
Dearborn 19
Poplar 19
Guangzhou 18
Lahore 18
Milan 17
Auburn Hills 16
Brasília 16
Dhaka 16
Medellín 16
Barnet 15
Bologna 15
Falkenstein 15
Jakarta 15
Mumbai 15
Curitiba 14
Vienna 14
Charlotte 13
Columbus 13
Ficarazzi 13
Florence 13
New Delhi 13
Totale 17.723
Salva come PNG Salva come JPEG
Nome #
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 178
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 174
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 172
BCOR gene alterations in hematological diseases 160
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 159
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) 152
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. 147
Anaplastic lymphoma kinase expression as a marker of malignancy. Application to a case of anaplastic large cell lymphoma with huge granulomatous reaction. 145
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biological and clinical features 144
Acute leukaemia immunophenotyping in bone-marrow routine sections. 141
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. 140
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. 140
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. 139
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma 139
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification 139
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 139
ARPIR: automatic RNA-Seq pipelines with interactive report 135
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features 132
Mutant NPM1 Maintains the Leukemic State through HOX Expression 129
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 129
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 129
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia 128
A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. 127
[The Haemolymphopathology Italian Group (H.I.G.): an essential resource for the new technical and organization problems troubling modern haemolymphopathology diagnostics] 127
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 126
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 126
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 126
NPM1 deletion is associated with gross chromosomal rearrangements in leukemia 125
"Designed" grafts for HLA-haploidentical stem cell transplantation. 123
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. 121
A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells 121
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial 121
Choroidal vasculature analysis in MEK inhibitor-associated retinopathy 120
Anaplastic large cell lymphoma: pathological, molecular and clinical features. 119
Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification 119
Acute Myeloid Leukemia with mutated nucleophosmin (NPM1). Any hope for a targeted therapy? 118
Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia 117
Genomics of Hairy cell leukemia 117
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: Final results of the GIMEMA LAL 0904 study 117
Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. 116
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance 116
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML 116
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia 115
Aggressive lymphomas: a convenient concept or an anatomo-pathological reality? 114
Exon-12 nucleophosmin (NPM) mutation and aberrant cytoplasmic expression of NPM protein in leukemia cell line OCI-AML3 113
L’esclusione degli anziani dai trial clinici in corso sul trattamento delle neoplasie ematologiche 113
Aberrant hypermutation of PIM1, PAX5, RhoH/TTF and cMYC in nodular lymphocyte predominance Hodgkin's disease 112
Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants 112
Antigen retrieval techniques in immunohistochemistry: comparison of different methods 112
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. 111
IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. 110
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23). 110
EML4-ALK rearrangement in non-small-cell lung cancer and non-tumor lung tissues. 109
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 109
T regulatory cell separation for clinical application. 109
Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. 108
Cellular localization and tissue distribution of PML proteins as defined by a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product. Preferential expression in postmitotic cells. 108
BRAF mutations in hairy-cell leukemia. 108
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 108
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. 108
Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin 108
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 108
Primay large B-cell lymphoma (PLBCL) of the retroperitoneum: a heterogeneous group of neoplasms, some of which mimic PLBCL of the mediastinum. 107
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 107
Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease 107
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML) 107
Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy 107
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 107
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 107
Nucleophosmin regulates the stability and transcriptional activity of p53. 106
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 106
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. 106
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. 105
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype 105
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE 105
HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse 105
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 104
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 104
Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 104
Richter's transformation in the heart 104
Bcl-6 protein expression in normal and neoplastic lymphoid tissues. 103
CD123 (IL-3R alpha) IS CONSISTENTLY EXPRESSED ON ACUTE MYELOID LEUKEMIA (AML) CARRYING NUCLEOPHOSMIN (NPM1) GENE MUTATION 103
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia 103
Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas 102
Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. 102
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. 102
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 101
MONOCLONAL ANTIBODIES PG-B6a AND PG-B6p RECOGNIZE, RESPECTIVELY, A HIGHLY CONSERVED AND A FORMOL-RESISTANT EPITOPE ON THE HUMAN BCL-6 PROTEIN AMINO-TERMINAL REGION. 101
CHARACTERIZATION OF A NEW MONOCLONAL ANTIBODY (PG-M3) DIRECTED AGAINST THE AMINOTERMINAL PORTION OF THE PML GENE PRODUCT: IMMUNOCYTOCHEMICAL EVIDENCE FOR HIGH EXPRESSION OF PML PROTEINS ON ACTIVATED MACROPHAGES, ENDOTHELIAL CELLS, AND EPITHELIA 101
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype 101
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature 101
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis 100
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. 100
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. 100
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin 100
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 100
Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity 99
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 99
Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT) 98
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases 98
Totale 11.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.614
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021856 0 0 0 0 0 0 0 0 0 102 229 525
2021/20222.962 70 550 79 184 109 41 30 785 71 161 452 430
2022/20234.805 333 868 48 405 388 537 6 220 1.716 62 165 57
2023/20241.763 128 194 102 48 18 20 406 30 151 53 303 310
2024/20254.551 132 477 182 148 610 182 239 396 930 249 624 382
2025/20269.438 812 599 416 1.118 1.345 930 1.642 555 1.234 787 0 0
Totale 28.983